For research use only. Not for therapeutic Use.
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma[1].
| Catalog Number | I042187 |
| CAS Number | 2043952-59-4 |
| Purity | ≥95% |
| Reference | [1]. Burgess G, et, al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018 Sep;35:67-75. |
